| General Information of Drug Metabolite (DM) (ID: DM019281) |
| DM Name |
NITD609 Metabolite M37
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
NITD609
|
[1] |
|
|
|
|
|
|
|
| DME(s) Metabolizing This DM |
| DME Name |
DME ID |
Product |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
NITD609
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| NITD609 |
DR3235
|
Phase 2 |
Malaria |
|
|
| References |
| 1 |
KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
